½÷¥ß¬ã¨s³¡§Ö°T
¬d¬Ý©õ¤é¬ã¨s³¡§Ö°T Âà±Hµ¹ªB¤Í §K¶O­q¾\ ·N¨£´£¨Ñ English Version
Phillip Home   6¤ë12¤é (¬P´Á¤T)

 

´ËªQ°ê»Ú(2155)
¸Ñºc¡G
´ËªQ°ê»Ú(2155)ªº¥DÀç·~°È¬°³]­p¡B»s³y¡B¦w¸Ë¥H¤Î¹BºûªA°È¡A¥D­nÀ³¥Î©ó¥]§t¤Æ¾Ç¤ÏÀ³¡B¥Íª«¤ÏÀ³©M»E¦X¤ÏÀ³ªº®Ö¤ß³]³Æ¡B¤uÃÀ¨t²Î¡]¦p¤uÃÀ¼Ò¶ô¡^¥H¤Î¾ãÅé¸Ñ¨M¤è®×¡]¦p¼Ò¶ô¤Æ¤u·~¸Ë¸m¡^¡C¥Ø«e¶°¹ÎªA°Èªº¤U´å¦æ·~/»â°ì¥]¬Aªo®ð·Ò¤Æ¡B¤é¤Æ¡B¤Æ¤u·s§÷®Æ¡B»sÃÄ¡]§t¥Íª«»sÃÄ©M¤Æ¾Ç¦X¦¨ÃÄ¡^¡B°Ê¤O¹q¦À­ì§÷®Æ¡]§tª÷ÄÝÄq¡B¾Y¹q¦À­ì§÷®Æ¡B¤¤¶¡¤Æ¤u­ì§÷®Æ¡^©M¹q¤l¤Æ¾Ç«~¡]§t¥ú¥ñ­ì§÷®Æ©M°ª¯Â«×¤Æ¾Ç¸Õ¾¯ªº¥Í²£¡^µ¥¡C¦b¯à·½§÷®Æ»â°ì¡A¶°¹Î«ùÄò²`¯Ñ©ó¶Ç²Îªo®ð·Ò¤Æ¡B¥Û¤Æ¡B¤Æ¤u¡B§Mª÷µ¥¦æ·~¡A¦P®É­P¤O©óºñ¦â/§CºÒ/¥i«ùÄò¯à·½©M³Ð·s·s§÷®Æµ¥¦h­ÓÁɹDªº¦P¨Bµo®i¡A¬°¤U´å«È¤á´£¨Ñ®Ö¤ß³]³Æ¡B¤uÃÀ¨t²Î©M¤uµ{¤@Åé¤Æ¸Ñ¨M¤è®×¡C¦b²M¼ä¯à·½¤è­±¡A¥h¦~¶°¹Î»P°ê»Ú¬Yª¾¦W²M¼ä§Þ³N¤½¥qñ­q¤F¥Íª«¿U®Æ¼Ò¶ô¤Æ¤u¼t ¶µ¥Ø¦X¬ù¡C¦bªo®ð·Ò¤Æ¤è­±¡A¶°¹Î´£¨Ñªº²{¥N¤Æ·Òªo¼t©Ò¥Í²£ªº¥Ûªo²£«~²Å¦X°ê»ÚÀô«O¼Ð·Ç¡A¯à°÷¦bÂX¤j·Òªo¼t²£¯àªº¦P®É¶i¤@¨B´£°ª¦¨«~ªoªº«~½è¡C¦b¤Æ¤u·s§÷®Æ¤è­±¡A¥h¦~¶°¹Î»P°ê¤º¬Y·s§÷®Æ¤½¥q´N¤A²m¤þ²m»Ä¦@»Eª«¤@´Á¤u¼t¶µ¥Øªº¶W°ªÀ£®Ö¤ß³]³Æñ­q¦X¬ù¡A¸Ó¶µ«Ø³]³W¼Ò¬ù¬°4 ¸U¾·/¦~¡C¦b¥Í©R¬ì§Þ»â°ì¡A¶°¹Î¥D­n±Mª`©ó»sÃÄ¡B¥Íª«»sÃÄ¡B§Ö³t®ø¶O«~¡B¤Æ§©«~µ¥¦æ·~©M»â°ìªº®Ö¤ß³]³Æ¡B¤uÃÀ¨t²Î©M¼Æ´¼¤Æ¾ãÅé¤uµ{¸Ñ¨M¤è®×ªº´£¨Ñ¡A¨äÂл\¤uµ{¿Ô¸ß¡B³]­p¡BÅçÃҿԸߡB¤uµ{©Ó¥]¡BÅçÃÒ°õ¦æ¡B¼Æ¦r¤Æ¹Bºûµ¥¥þ¥Í©R¶g´ÁªºªA°È¡C©ó2023¦~¡A¶°¹Î·sñ­q³æª÷ÃB77.84»õ¤¸¤H¥Á¹ô¡A¼Wªø¥D­n¨Ó¦Û©ó»sÃÄ©M¥Íª«»sÃÄ¥H¤Î¤Æ¤u¦æ·~/»â°ì¡A¸Ó¨â­Ó¦æ·~/»â°ìªº·sñ­q³æª÷ÃB¦û¶°¹Î·sñ­q³æÁ`ÃBªº¤ñ¨Ò¶W¹L50%¡C¥R¨Kªº¦b¤â­q³æ¥H¤Î°ªªþ¥[­È§t¶qªº·~°È¯à°÷¨Ï¶°¹Îªº¬Õ§Q¤ô¥­«O«ù´£¤É¡A½T«O¶°¹Î¦b2024¦~¹ê²{¥i«ùÄòªº°ª½è¶q¼Wªø¡C(µ§ªÌ¨S¦³«ù¦³¤W­zªÑ²¼)
µ¦²¤¡G
¶R¤J»ù$5.70¡A¥Ø¼Ð»ù$6.30¡A¤î»k»ù$5.40
 

»·¤jÂåÃÄ(512)
¸Ñºc¡G
»·¤jÂåÃÄ¡]00512¡^ºI¦Ü2023¦~12¤ë©³¤î¦~«×ªº¦¬¯q¬ù105.30»õ¤¸¡]´ä¹ô¡D¤U¦P¡^¡A¦P¤ñ¼Wªø¬ù10.1%; ¦pºJ°£¤H¥Á¹ô»P´ä¤¸¶×²vÅܰʪº¼vÅT¡A¸û2022¦~¦P´Á¬Û¤ñ¤Wº¦¬ù15.8%¡CÀ³¦û´Á¤º¥¿±`¤Æ·¸§Q¬ù¬°20.36»õ¤¸¡A¦P¤ñ¤U­°¬ù4.7%¡A¦pºJ°£¤H¥Á¹ô»P´ä¤¸¶×²vÅܰʪº¼vÅT¡A¸û2022¦~¦P´Á¬Û¤ñ¤Wº¦¬ù0.2%¡C¦~¤º¡A¦@¦³30´Ú²£«~Àò§å¤W¥«¡B¹ê²{3¶µ­«¤j¨ÖÁÊ¡A¨Ã¾Ö¦³5­Ó§Þ³N¥­¥x©M8­Ó¬ãµo¤¤¤ß¡A¶W200­ÓÂå«O¥Ø¿ý²£«~¡A¹L»õ²£«~16­Ó¡C¾Ô²¤©Ê¦¬ÁʤѬz¥ÐÃä¤Î­«¼y¦h´¶®õÂåÃĬì§Þ¡AÀò±o¤ß¸£¦åºÞ¡B­G¸z¹D¯e¯fµ¥ºC¯f»â°ì¤Q¾l´Ú²£«~¡A¹ê²{±q«æ·m±Ï¨ìºC¯fºÞ²zªº²`«×Âл\¡F¨Ã¦³·s«¬¿ï¾Ü©ÊîÇ©TନüÅé«ú§Ü¾¯¡]MRA¡^ÃĪ«¨Ì´¶§QଥH¤Î¨u¨£¯fÃĪ«¥d¨¦®ò»Ä¤À´²¤ùÀò§å¤W¥«¡A§¡¬°°ê¤º­º¥é¡C2024¦~¡A°ò©óÅãµÛªºÁ{§ÉÀø®Ä©M«e´ÁÂå°|­ã¤J©MÂå¥Í°ö°V¤u§@ªº¾Q¶}¡A©ö¥Ì®õÐÀ[90Y]·L²yª`®g²G¦³±æ«ùÄò©ñ¶q¡C¦P®É¡A¤½¥q¦b©I§l¤Î¦M­«¯g»â°ì¡A±N¥þ¤O±À¶iSTC3141°ê¤ºÁw¬r¯g¢º´ÁÁ{§É¬ã¨s¡Aª§¨ú¦­¤é¶ñ¸É¦æ·~ªÅ¥Õ¡F¦b¤ß¸£¦åºÞ¾¹±ñ»â°ì¡A¤½¥q¤w¥´³y¥X»á¨ãÀu¶Õªº°ªºÝÂåÀø¾¹±ñ²£«~¶°¸s¨Ã¶¶§Q±À°Ê¦h´Ú²£«~¤W¥«¡A«áÄò±NÄ~Äò³ò¶³q¸ôºÞ²z¡Bµ²ºc©Ê¤ßŦ¯f¡B¹q¥Í²z¤Î¤ß°I¤T­Ó¤è¦V¡AÀu¤Æ²£«~µ²ºc¤Î¸ê·½°t¸m¡A¼W¥[ºÞ½u¨ó¦P©Ê¡A¨Ã¹ê²{²£«~¤À¶¥¬q¤À±è¦¸¤W¥«¡C
µ¦²¤¡G
¶R¤J»ù$4.82¡A¥Ø¼Ð»ù$5.32¡A¤î»k»ù$4.48

ùÚ¦w°ê»Ú (1044.HK) - FY2023·~°È¤´¿ý±oí°·¼Wªø¡B°ªºÝ°ª¤ò§Q²£«~«ùÄò¼Wªø
ùÚ¦w°ê»Ú³Ð¥ß©ó1985¦~¡A¬O¥Ø«e°ê¤º³Ì¤jªº¥Í¬¡¥Î¯È©M°ü¥®½Ã¥Í¥Î«~»s³y°Ó¡AºX¤U¾Ö¦³¦wº¸¼Ö¡B¤ß¬Û¦L¡B¤C«×ªÅ¶¡¡B¦w¨à¼Ö¥|ªT¤¤°ê¹£¦W°Ó¼Ð¡A½Ã¥Í¤y¡B¯È§¿¿Ç¡B¥Í¬¡¥Î¯È¤T¤j¥D¾É²£«~¦b°ê¤º¥«¦û²v¦W¦C«e­T¡C......§ó¦h

2024¦~²Ä¤@©u¡G´¼¯à¤â¾÷¥«³õªº°ª¶¥¤ÆÁͶÕ

ÀHµÛ2024¦~²Ä¤@©uªºµ²§ô¡A¥þ²y´¼¯à¤â¾÷¥«³õ¦A¦¸ÃÒ©ú¤F¨ä«ùÄòªº¦¨ªø°Ê¯à©M§Þ³Nºt¶iªº§Ö³t¨B¥ï¡C®Ú¾ÚCounterpoint Researchªº¼Æ¾Ú¡A¥þ²y´¼¯à¤â¾÷¥X³f¶q¦~¼W6%¡A¦ÓÁ`¦¬¤J§ó¬O¦~¼W7%¡A¹F¨ì­º©u¾ú¥v·s°ª¡C³o¶µ¦¨ÁZªº¨ú±o¡A¥D­n±o¯q©ó·s¿³¥«³õªº±j«l»Ý¨D¥H¤Î°ªºÝ³]³......§ó¦h


  • ¬ü°ê¯à·½¸ê°T§½(EIA)½Õ°ª·í¦a¤µ¦~­ìªo²£¶q¼Wªø¹w´ú¡A³Ð¬ö¿ý·s°ªªº²£¶q¤ô¥­¸û­ì¥ý¦ô­p¬°°ª¡A¦ý¦P®É½Õ§C©ú¦~²£¶q¹w´ú¡CEIA¦b³Ì·s¤½¥¬ªºµuÆ[³ø§i¤º¦ô­p¡A¬ü°ê¤µ¦~¥Ûªo¤é§¡²£¶q±N¤W¤É31¸U±í¡A­ì¥ý¦ô­p¬ù¬°4¸U±í¡A²£¶q±N¹F1324¸U±í¡F©ú¦~²£¶q«h½Õ§C¬°1371¸U±í¡A­ì¥ý¬°1373¸U±í¡C
  • ¤¤°ê­¼Áp·|¤½¥¬¡A5¤ë¥þ°ê­¼¥Î¨®¥«³õ¹s°â171¸U½ø¡A«ö¦~¶^1.9%¡A«ö¤ë«h¼Wªø11.4%¡F­º5­Ó¤ë¹s°â807.3¸U½ø¡A«ö¦~¼W5.7%¡C5¤ë·s¯à·½¨®¥«³õ¹s°â80.4¸U½ø¡A«ö¦~¼Wªø38.5%¡A«ö¤ë¼Wªø18.7%¡C·s¯à·½¨®°ê¤º¹s°âº¯³z²v¬°47%¡A³Ð¾ú¥v·s°ª¡A«ö¦~´£¤É14­Ó¦Ê¤ÀÂI¡C
  • °ê»Ú°]¸g
    • ¥þ¬ü¿W¥ß¥ø·~Áp·ù(NFIB)¤½¥¬¡A5¤ë¬ü°ê¤p«¬¥ø·~«H¤ß«ü¼Æ³ø90.5¡A«ö¤ë¤É0.8¡A¬O³sÄò²Ä¤G­Ó¤ë¤W¤É¡C«ü¼Æ¦b3¤ë´¿¶^¦Ü2012¦~11¤ë¥H¨Ó³Ì§C¤ô¥­¡C¦P®É¡ANFIB½s¨îªº¤£©ú®Ô«ü¼Æ¦b5¤ë¤W¤É9°òÂI¡A¦Ü85¡A¬O2020¦~11¤ë¥H¨Ó³Ì°ª¼Æ¦r¡C
    • ¤pÄP¨T¨®(09868)·L³Õ©«¤å¡A¤½¥¬ºX¤U·s«~µPMONA¨t¦C­º´Ú¨®«¬©w¦W¬°¡u¤pÄPM03¡v¡C¤pÄP¨T¨®¸³¨Æªø¤Î­º®u°õ¦æ©x¦ó¤pÄP5¤ë®Éªí¥Ü¡A·s«~µPMONAªº­º´Ú²£«~¤DA¯Å¯Â¹qÃ⨮¡A±N©ó6¤ëµo¥¬¡A²Ä¤T©u¥¿¦¡¤W¥«¤Î¥æ¥I¡C
    • ·sµØªÀ³ø¹D¡A°ê®a¥D®u¡B¤¤¥¡¥þ­±²`¤Æ§ï­²©e­û·|¥D¥ô²ßªñ¥­¤µ¤é¤U¤È¥D«ù¥l¶}¤¤¥¡¥þ­±²`¤Æ§ï­²©e­û·|²Ä¤­¦¸·|ij®É±j½Õ¡A§¹µ½¤¤°ê¯S¦â²{¥N¥ø·~¨î«×¡A¥²¶·þÓ²´©óµo´§¤¤°ê¯S¦âªÀ·|¥D¸q¨î«×Àu¶Õ¡A¥[±jÄÒªº»â¾É¡A§¹µ½¤½¥qªv²z¡A±À°Ê¥ø·~«Ø¥ß°·¥þ²£Åv²M´·¡BÅv³d©ú½T¡B¬F¥ø¤À¶}¡BºÞ²z¬ì¾Çªº²{¥N¥ø·~¨î«×¡A°ö¨|§ó¦h¥@¬É¤@¬y¥ø·~¡C
  • ¥D­nÉ]³õ
    • AªÑ¦bºÝ¤È¸`¤pªø°²´Á«á´_¥«­Ó§Oµo®i¡A¤WÃÒ«ü¼Æ§C¶}§C¨«¡A³Ì¦h¶^37ÂI©Î1.23%¡A§C¨£3013ÂI¡A¥þ¤é¦¬¥«³ø3028ÂI¡A¶^23ÂI©Î0.76%¡A¦¨¥æ3326.83»õ¤¸¤H¥Á¹ô¡C²`¦¨«ü³Ì¦h¶^89ÂI©Î0.96%¡A§C¨£9166ÂI¡A¤È«á¦³¶R½L§l¯Ç¡A¤j¥«¦^í¡A³Ì¦h¤É27ÂI©Î0.29%¡A°ª¨£9282ÂI¡A¥þ¤é¦¬¥«³ø9262ÂI¡A¤É6ÂI©Î0.07%¡A¦¨¥æ3702.32»õ¤¸¡C¥«³õ¥æ§ëÁͲHÀR¡A¨â¥«¦¨¥æ¦X­pÁY´î¦Ü7029»õ¤¸¡C
    • ¨È¤Ó°ÏªÑ¥«­Ó§Oµo®i¡A¥«³õÃöª`ÁpÀx§½©P¤G°_¤@³s¨â¤éij®§·|ij¡C¤é¥»ªÑ¥«³s¤É¨â¤é¡A¤é¸g¥­§¡«ü¼Æ¦¬³ø39134ÂI¡A¤É96ÂI©Î0.25%¡C
    • ¬ü°êÁpÀx§½¥l¶}ij®§·|ij¤§»Ú¡A¼Ú¬w¬F§½¤£Ã­ªº¼~¼{¶i¤@¨B§xÂZ¥«³õ¡A¬üªÑ©P¤G¦b»È¦æªÑ©ß°â¤U¨üÀ£¡A¹D«ü§C¶}72ÂI«á±Û§Y¤U´¡421ÂI¡A§C¨£38446ÂI¡F¼Ð«ü´¿®À0.63%¡A¯Ç«ü¶^0.49%«á¡A»P¼Ð«ü»ôÂà¤É¨ÃÄò³Ð¦¬¥«·s°ª¡A¥D­n¦]¬°Ä«ªG±a°Ê¬ì§ÞªÑªO¶ô³Ð¾ú¥v·s°ª¡F¹D«ü«hÁY¯¶¶^¶Õ¡C¬ü¥«¦¬¥«¡A¹D«ü¶^´TÁY¦Ü120ÂI©Î0.31%¡A³ø38747ÂI¡F¼Ð«üÂ຦0.27%¡A³ø5375ÂI¡A¬ì§ÞªO¶ô©â°ª1.7%¡F¯Ç«ü­Ë¤É0.88%¡A³ø17343ÂI¡C
  • Àô²yºîµû
    • ¥«³õÀR«Ý¬ü°ê³qµÈ¼Æ¾Ú»PÁpÀx§½¤½¥¬Ä³®§µ²ªG¡A¥H¿Å¶q·í§½¦ó®É±Ò°Ê´î®§¡A¬ü¤¸¶×»ù©P¤G³y¦n¡A³Ð¤U¥|©P·s°ª¡C¼Ú¬w¬F§½¤£©ú®Ô¡A¼Úù°¾³n¡C¬ü¶×«ü¼Æ°ª¨£105.459¡A¬O5¤ë14¤é¥H¨Ó³Ì±j¤ô¥­¡A¤É´T¬°0.29%¡C

    ¥«³õÆ[±æÁpÀx§½Ä³®§µ²ªG¤Î¬ü°ê³qµÈ¼Æ¾Ú¡A²{³fª÷»ù¾aí¡C¬ü¤¸¶×»ù§e±j¡A­­¨î¤Fª÷»ù¤É¶Õ¡C¯Ã¬ù´Áª÷¦¬¥«¶^40¬ü¥P¡A¨C¯s´µ³ø2326.60¬ü¤¸¡C...... §ó¦h

    ¦ÊÀÙ¯«¦{ (6160.HK)
    ¬ã¨s³ø§i: ¦ÊÀÙ¯«¦{(6160.HK) : ¥Ø¼Ð»ù122.00´ä¤¸¡C¦ÊÀÙ¯«¦{¦¨¥ß©ó 2010 ¦~¡A¬O¥»¤g³Ð·sÃÄ¥X®üÀsÀY¡A»EµJ¤_¸~½Fªº³Ð·s«¬¤À¤l¹v¦V¤Î¸~½F§K¬ÌªvÀøÃĪ«ªº¬ãµo¤Î°Ó·~¤Æ¡A¬O­º®a¹ê²{¬üªÑ+HªÑ+AªÑ¤T¦a¤W¥«ªº³Ð·sÃÄ¥ø·~¡C¤½¥q¹ê¤O¨ô¶V¡A¨ã³Æ¦­´ÁÃĪ«µo²{¡BÁ{§É¬ã¨s¡B³W¼Ò¤Æªº°ª½è¶qÃĪ«¥Í²£¤Î°Ó·~¤Æµ¥¥þ¤è¦ì¤@Åé¤Æ¯à¤O¡C¤½¥qªº¥|­Ó¥D­nªÑªF¥]¬A¦w¶i¡BBaker Brothers Life Sciences, L.P.¤Î¨ä¤@­P¦æ°Ê¤H¡BHHLR Fund, L.P.¤Î¨ä¤@­P¦æ°Ê¤H¡BCapital Research and Management Company ¤Î¨ä¤@­P¦æ°Ê¤H¤À§O«ùªÑ 18.25%¡B11.30%¡B10.89%¡B7.92%¡A¨ä¤¤³Ì¤jªÑªF¦w¶i¡A¬O¥þ²y±Æ¦W«e20 ¦ìªº¥Íª«ÂåÃĤ½¥q¡C¦ÊÀÙ¯«¦{ªººÞ½u«p«×¤Î¦h¼Ë¤Æµ{«×¦ì©~¥þ²yÄvª§«e¦C¡C¥Ø«e³B©óÁ{§É¤Î°Ó·~¤Æ¶¥¬qªºÃĪ«¬ù 50 ­Ó¡A¤w¤W¥«ÃĪ« 16 ­Ó¡]¥]¬A¦Û¬ã²£«~ 3 ­Ó¡^¡A³B©óÁ{§É¢»´Á¶¥¬qªºÃĪ« 3­Ó¡A³B©óÁ{§É¢º´Á¶¥¬qªºÃĪ« 13 ­Ó¡A³B©óÁ{§É¢¹´Á¶¥¬qªºÃĪ« 18 ­Ó¡C¥t¥~¾Ö¦³ 60 §E¶µÁ{§É«e·sÃĶµ¥Ø¡A³o¨ÇÃĪ«Ãþ«¬¯A¤Î¤p¤À¤lÃÄ¡B³æ§Ü¡BÂù§Ü¡BADC µ¥¦hºØÃþ«¬¡A¦h´ÚÃĪ«¨ã³Æ®t²§¤Æ¤D¦Ü¡§first-in-class¡¨¼ç¤O¡CÂ×´I¡B¦h¤¸¤Æªº¬ãµoºÞ½u¼sªxÂл\¤F¥þ²y 80%ªºÀù¯gÃþ«¬¡]«öµo¯f²v­pºâ¡^¡C¦b¦Û¬ã¤è­±¡A¦ÊÀÙ¾Ö¦³¨ô¶Vªº¤º³¡¶}µo¯à¤O¡A¾Ö¦³¶W 900 ¤HªºÁ{§É«e¬ã¨s¹Î¶¤¡A¦Û¥D¬ãµo²£«~¤¤¥Ø«e¦@¦³ 11 ´Ú²£«~¶i¤J¨ì°Ó·~¤Æ¶¥¬q¤ÎÁ{§É¹êÅ綥¬q¡A¨ä¤¤¦³ 3 ´Ú¤w¸gÀò§å¤W¥«¡A¤À§O¬°¿A¥¬´À¥§½¦Ån¡B´À¹p§Q¯]³æ§Üª`®g²G¡B©¬¦Ì©¬§Q½¦Ån¡A¥t¥~ 8 ´Ú²£«~³B©óÁ{§É¹êÅ綥¬q¡A¥B¬°®t²§¤Æ³]­pªº³Ð·sÃĪ«¡C¦b¦X§@¤è­±¡A¦ÊÀÙ¯«¦{ License in/out±j¤j¡ABD ¯à¤O³B©ó¥þ²y«e¦C¡A2017 ¦~»P·s°ò¤½¥q¡]²{ÁõÄݤ_¦Ê®É¬ü¬I¶QÄ_¡^¹F¦¨¦X§@¡A2019 ¦~©³»P¦w¶i­q¥ß¦X§@¨óij¡A2021 ¦~ 1 ¤ë»P 12 ¤ë¤À§O»P¿ÕµØ¹F¦¨¦X§@¡A¥ý«á¤Þ¶i13 ´Ú°Ó·~¤Æ²£«~ªº¤¤°êÅv¯q¡A¥]¬A¦w¶iªº¦w¥[ºû¡B­¿§Q§´¡B³Í¬¥´µ¡ABMS ªº·ç½Æ¬ü¡Bºû¹F²ï¡AEUSAPharmaªºÂÄ·ÅÏÈ¡B³Í¿A¦Ê¡A¦Ê¶ø®õªº´¶¨©§Æ¡A¥H¤Î¿ÕµØªº®õµá¼Ö¡BÁÚ¦NÚ¬¡Bºû¥þ¯S¡B­¸¥§§´¡BÃÙ¥i¹Fµ¥³Ð·s²£«~¡C¤½¥q¦bÁ{§É¶}µo¡BÁ{§Éµ¦²¤¡BÁ{§É°õ¦æµ¥¤è­±´I¦³¸gÅç¡A¥Ø«e¦b¥þ²y¾Ö¦³3,500+¥B¤´µM¤£Â_¼Wªøªº°Ó·~¤Æ¹Î¶¤¡A¨ä¤¤¤¤°ê¹Î¶¤3,000+¦W¡AÂл\¶W¹L 1,000 ®aÂå°|¡C¤½¥qªº¬ãµo§G§½¤wÂл\ ADC¡BÂù§Ü/¦h§Ü¡BCDAC¡]PROTAC¡^¡BCAR-NK¡BmRNA µ¥¦b¤ºªº¦hºØ¤j/¤p¤À¤lÃĪ«¥H¤Î·sªºÃĪ«§Î¦¡¡A¹w­p±N¦³±æ±a¨Ó«ùÄòªº³Ð·s²£«~¿é¥X¡C°]°È¼Æ¾ÚÅã¥Ü¡A¤½¥qªñ¤­¦~Àç·~¦¬¤J¡B²£«~Á`¦¬¤J¤Î®Ö¤ß²£«~¦¬¤J«ùÄò«O«ù°ª³t¼Wªø¡A¬ãµo¶O¥Î¤Î¾P°â/ºÞ²z¶O¥Î¼W³t«ùÄò©ñ½w¡A¨ä¸gÀçÁ«·l¦b 2022 ¦~ªï¨Ó­º¦¸´îÁ«¡A¸gÀç©Ê¬Õ§Q©äÂI¦³±æ¨ì¨Ó¡C2023¦~¡A¤½¥q¹ê²{Àç·~¦¬¤J174.2 »õ¤¸¡A¤ñ¤W¦~¦P´Á¼W¥[82.13%¡F¹ê²{²bÁ«·l67.2 »õ¤¸¡A¤ñ¤W¦~¦P´Á´î¤Ö69.3 »õ¤¸¡F³ø§i´Á¤º¡A¸gÀ笡°Ê²£¥Íªº²{ª÷¬y¶q²bÃB¬°-77.9»õ¤¸¡F¥þ¦~¬ãµo§ë¤J¬°128.1 »õ¤¸¡A»P¤W¦~¦P´Á¬Û¤ñ¼Wªø14.90%¡C2024¦~¤@©u«×¡A¤½¥q¹ê²{Àç·~¦¬¤J53.59»õ¤¸¡A¦P¤ñ¼Wªø74.8%¡F¹ê²{ÂkÄݤ_¤W¥«¤½¥qªÑªFªº²b§Q¼í-19.08»õ¤¸¡A¤W¦~¦P´Á¬°-26.13»õ¤¸¡AÁ«·l¦P¤ñÁY¤p¡C¦ÊÀÙ²£«~²Õ¦X¤´³B©ó°ª³t¼WªøºA¶Õ¡A¦b²£«~¦¬¤J«O«ù°ª¼W³tªº±¡ªp¤U¡A¤½¥qªº¥«­È¤ô¥­±N«ùÄò´£¤É¡C


    ¥«ªp¤ÀªR¡G¨È¤Ó°ÏªÑ¥«­Ó§Oµo®i¡A¥«³õÃöª`ÁpÀx§½©P¤G°_¤@³s¨â¤éij®§·|ij¡C¤é¥»ªÑ¥«³s¤É¨â¤é¡A¤é¸g¥­§¡«ü¼Æ¦¬³ø39134ÂI¡A¤É96ÂI©Î0.25%¡C......§ó¦h

    ¥»¦a«ü¼Æ
           ÂI¼Æ    ¤É¶^   ¤É¶^%

    Àô²y«ü¼Æ
           ÂI¼Æ    ¤É¶^   ¤É¶^%

    A-H·¸»ù(§éÅý) ªí
    ¥N¸¹ ¤½¥q¦WºÙ H ªÑ
    ¦¬¥«»ù
    A ªÑ
    ¦¬¥«»ù
    A - H
    ·¸»ù

    ¨ä¥L
       ÂI¼Æ     ¤É¶^   ¤É¶^%
      
      


    ®ü¥~¬ã¨s³ø§i


    §ë¸êªA°È¤¤¤ß


    ¬d¸ß¼ö½u¡G2277 6666 ©Î investornotes@phillip.com.hk
    ¦pªG­¶­±Åã¥Ü¤£¥¿±`½ÐÂIÀ» ¦¹³B¬d¬Ý³sµ²©ó¸Uºûºô¤Wªºª©¥»¡C
     

    ¥»¤å©Ò¥]§tªº¸ê®Æ§¡¬°½÷¥ßµý¨é(­»´ä)¦³­­¤½¥q©Î¨äªþÄݤ½¥q (¡u¶°¹Î¡v) ±q¬Û«H¬°·Ç½Tªº¨Ó·½·j¶°¡A¦ý¹ï¥ô¦ó¦]«H¿à©Î°Ñ¦Ò¦³Ãö¤º®e©Ò¾É­Pªº·l¥¢¡A·§¤£­t³d¡C¥»¶°¹Î (©Î¨ä¹µ­û) ¥i¯à«ù¦³¥»¤å©Ò­z¦³Ãöªº§ë¸ê²£«~¡C¦UÃþ²£«~ªº­·ÀI¡A½Ð°Ñ¾\¥»¤½¥qºô­¶ http://www.phillip.com.hk¡m­·ÀI©ÜÅSÁn©ú¡n¡C

    ¦p±z¤£·Q¦A¦¬¨ú¹q¤l±À¼s¶l¥ó¡A½Ð«ö¦¹³B¡C

    ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

    Copyright(C) 2024 Phillip Securities (HK) Ltd. All Rights Reserved.